Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HLCS | P50747 | 3/20 | 0.51 |
| ▸ | KRAS | P01116 | 9/20 | 0.50 |
| ▸ | HINT1 | P49773 | 1/20 | 0.47 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.42 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25893248 | 0.94 | KRAS (0.57) | HLCSKRASHINT1FUT5F2 | |
| SCHEMBL25890806 | 0.90 | HLCS (0.48) | HLCSKRASHINT1FUT5F2 | |
| SCHEMBL25893244 | 0.85 | FUT6 (0.53) | HLCSKRASFUT5F2TGM2 | |
| SCHEMBL25891100 | 0.83 | KRAS (0.52) | KRASFUT5TGM2B4GALT1 | |
| SCHEMBL25890782 | 0.83 | KRAS (0.52) | KRASFUT5TGM2B4GALT1 | |
| SCHEMBL14204794 | 0.81 | HLCS (0.69) | HLCSHINT1 | |
| SCHEMBL14204804 | 0.81 | HLCS (0.69) | HLCSHINT1 | |
| SCHEMBL14204815 | 0.81 | KRAS (0.60) | HLCSKRASHINT1FUT5F2 | |
| SCHEMBL14204813 | 0.81 | KRAS (0.60) | HLCSKRASHINT1FUT5F2 | |
| SCHEMBL14204788 | 0.80 | HLCS (0.72) | HLCSHINT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | GLYCO-THERAPY BIOTECHNOLOGY CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | FUT5, FUT6, SIGLEC7 | HLCS 1173/4885KRAS 4257/4885HINT1 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.